Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis

scientific article published on 24 March 2017

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.5213/INJ.1732646.323
P8608Fatcat IDrelease_mxc6wfwlibf3pgd6cyijzhowku
P932PMC publication ID5380821
P698PubMed publication ID28361515

P50authorYuanshan CuiQ89088688
Zhenli GaoQ89088690
Hejia YuanQ96037692
Jitao WuQ96037694
Peng PengQ96037696
Xujie SunQ96037699
P2093author name stringJitao Wu
Zhenli Gao
Peng Peng
Yuanshan Cui
Hejia Yuan
Xujie Sun
P2860cites workEfficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.Q53155089
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.Q53317478
Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary resultsQ74206910
Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind studyQ80973713
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month studyQ81833229
Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosisQ83445672
Botulinum Toxin-A Injections Into Neurogenic Overactive Bladder—To Include or Exclude the Trigone? A Prospective, Randomized, Controlled TrialQ85205665
OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic reviewQ26826756
Meta-analysis in clinical trialsQ27860779
Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder.Q33915263
The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence SocietyQ35057109
Synaptic transmission: inhibition of neurotransmitter release by botulinum toxinsQ35187504
Adverse events after botulinum A toxin injection for neurogenic voiding disordersQ36059392
Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity.Q36373708
Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?Q36574048
Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysisQ36804908
OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiologyQ37299990
EAU guidelines on neurogenic lower urinary tract dysfunctionQ37464377
OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivityQ37536741
Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: a literature overviewQ37951376
Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and EfficacyQ39825759
Vesico-ureteric reflux in adult patients with spinal injury.Q41513979
Urinary tract infection in patients with neurogenic bladder dysfunctionQ43555532
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivityQ44539406
New therapeutic options for refractory neurogenic detrusor overactivityQ44934769
Epidemiology and healthcare utilization of neurogenic bladder patients in a us claims databaseQ46560975
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivityQ46586297
European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivityQ47892069
Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of lifeQ47966680
Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivityQ48389748
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trialQ48621733
Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany.Q49073287
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P433issue1
P921main subjectbotulinum toxin type AQ4095199
P304page(s)53-61
P577publication date2017-03-24
P1433published inInternational neurourology journalQ26842093
P1476titleEfficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
P478volume21

Reverse relations

Q91768465Guideline for the management of pre-, intra-, and postpartum care of women with a spinal cord injurycites workP2860

Search more.